title: [Safety of use of micronized diosmin at daily doses up to 2000 mg per day].
abstract: Formulations of micronized diosmin (MPFF) are widely used in the treatment of chronic venous disease, hemorrhoidal disease and other indications. The usual recommended dose of micronized diosmin is 1000 mg once daily. Numerous studies confirm the superior efficacy and safety of higher doses of diosmin up to 2000 mg per day in a few months therapy.
  
  
  OBJECTIVE
  The aim of the study was to observe the efficacy and safety of micronized diosmine used in a daily dose of 1000 and 2000 mg for 4 months.
  
  
  METHODS
  The study involved 327 patients meeting the inclusion and exclusion criteria. The parameters were measured immediately prior to the first dose and at 2 and 4 months of therapy. The safety analysis was conducted and the results obtained from measured parameters are presented in tables.
  
  
  RESULTS
  No significant abnormalities in the following parameters were observed: complete blood cell count, fibrinogen level, the level of alanine transaminase and aspartate, the level of urea and creatinine, urinalysis. The therapy did not affect the level of systolic and diastolic blood pressure. There was no significant adverse events in the study groups.
  
  
  CONCLUSIONS
  Cited in this publication results of a clinical study support the use of micronized diosmin at doses up to 2000 mg per day.
authors.affiliation: Specialist Medical Practice DAGDERM in Warsaw.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Staniewska
mesh_terms: D000293:Adolescent; D000328:Adult; D004145:Diosmin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D061214:Patient Safety; D011897:Random Allocation; D055815:Young Adult
chemical_list: D004145:Diosmin
keywords: Diosmin; safety therapy; venous insufficiency